Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Phase 1

Recruiting

Conditions: Plasma Cell Myeloma Refractory

Interventions: Drug: Isatuximab
Drug: Dexamethasone
Drug: Pegenzileukin
Drug: Pomalidomide
Drug: SAR439459
Drug: Belantamab mafodotin
Drug: Belumosudil
Drug: Evorpacept

First Posted Date: 2020-11-24

Last Posted Date: 2025-05-22

Lead Sponsor: Sanofi

Target Recruit Count: 197

Registration Number: NCT04643002

Locations: 🇬🇷
Investigational Site Number : 3000001, Athens, Greece
🇺🇸
University of Michigan Health System - Ann Arbor- Site Number : 8400004, Ann Arbor, Michigan, United States
🇺🇸
Roswell Park Cancer Institute- Site Number : 8400008, Buffalo, New York, United States

and more 22 locations

Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.

Phase 2

Completed

Conditions: Pneumococcal Immunization

Interventions: Biological: Pneumococcal Vaccine Polyvalent-Pneumovax 23
Biological: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb
Biological: Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII
Biological: Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI
Biological: Pneumococcal 13 - valent conjugate vaccine-Prevnar 13

First Posted Date: 2020-10-12

Last Posted Date: 2024-08-27

Lead Sponsor: Sanofi

Target Recruit Count: 750

Registration Number: NCT04583618

Locations: 🇺🇸
Coastal Carolina Research Center - N Charleston Site Number : 8400004, North Charleston, South Carolina, United States
🇺🇸
Velocity Clinical Research, Medford Site Number : 8400010, Medford, Oregon, United States
🇺🇸
Preferred Primary Care Physicians Site Number : 8400009, Pittsburgh, Pennsylvania, United States

and more 14 locations

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

Phase 2

Completed

Conditions: Sjögren's Syndrome
Sjogren's Syndrome

Interventions: Drug: Placebo
Drug: SAR441344

First Posted Date: 2020-10-01

Last Posted Date: 2024-11-11

Lead Sponsor: Sanofi

Target Recruit Count: 84

Registration Number: NCT04572841

Locations: 🇨🇱
Investigational Site Number : 1520001, Santiago, Reg Metropolitana De Santiago, Chile
🇨🇱
Investigational Site Number : 1520004, Viña del Mar, Valparaíso, Chile
🇲🇽
Investigational Site Number : 4840002, Mexicali, Baja California, Mexico

and more 33 locations

Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)

Active, not recruiting

Conditions: Asthma

Interventions: Drug: Dupilumab SAR231893

First Posted Date: 2020-09-16

Last Posted Date: 2024-05-30

Lead Sponsor: Sanofi

Target Recruit Count: 375

Registration Number: NCT04550962

Locations: 🇰🇼
Investigational Site Number : 4140001, Kuwait, Kuwait
🇦🇷
Investigational Site Number : 0320004, Santa Fe, Argentina
🇨🇴
Investigational Site Number : 1700009, Barranquilla, Colombia

and more 38 locations

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Phase 2

Terminated

Conditions: Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Interventions: Drug: SAR408701 (Tusamitamab ravtansine)
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2020-08-24

Last Posted Date: 2025-03-17

Lead Sponsor: Sanofi

Target Recruit Count: 57

Registration Number: NCT04524689

Locations: 🇺🇸
KU Medical Center_Investigational Site Number :8400002, Westwood, Kansas, United States
🇧🇷
Centro Avancado de Oncologia CECAN - Liga Contra o Cancer Site Number : 0760004, Natal, Rio Grande Do Norte, Brazil
🇨🇱
Centro de Investigacion y Desarrollo Oncologico (CIDO) Hochstetter 599 of. 602-603-1001, Temuco_Investigational Site Number :1520005, Temuco, La Araucanía, Chile

and more 19 locations

First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

Phase 1

Completed

Conditions: Overweight
Healthy Subjects

Interventions: Drug: SAR441255
Drug: placebo

First Posted Date: 2020-08-20

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 48

Registration Number: NCT04521738

Locations: 🇺🇸
Investigational site number 8400001, Knoxville, Tennessee, United States

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: SAR231893
Drug: Placebo

First Posted Date: 2020-08-06

Last Posted Date: 2024-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 202

Registration Number: NCT04502862

Locations: 🇺🇸
Todd Astor MD Site Number : 8400016, Culver City, California, United States
🇺🇸
Kern Allergy and Medical Research. Inc. Site Number : 8400003, Bakersfield, California, United States
🇺🇸
Southern California Institute for Respiratory Diseases Site Number : 8400009, Los Angeles, California, United States

and more 52 locations

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Amcenestrant-matching placebo
Drug: SAR439859
Drug: Palbociclib
Drug: Letrozole
Drug: Letrozole-matching placebo
Drug: Goserelin

First Posted Date: 2020-07-20

Last Posted Date: 2023-12-08

Lead Sponsor: Sanofi

Target Recruit Count: 1068

Registration Number: NCT04478266

Locations: 🇺🇸
Investigational Site Number :8400029, Santa Monica, California, United States
🇺🇸
Investigational Site Number :8400038, Fullerton, California, United States
🇺🇸
Investigational Site Number :8400013, Westwood, Kansas, United States

and more 246 locations

A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19

Phase 1

Completed

Conditions: Corona Virus Infection

Interventions: Drug: Placebo
Drug: SAR443122

First Posted Date: 2020-07-14

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 68

Registration Number: NCT04469621

Locations: 🇦🇷
Investigational Site Number 0320001, Caba, Argentina
🇨🇱
Investigational Site Number 1520003, Santiago, Chile
🇷🇺
Investigational Site Number 6430002, Moscow, Russian Federation

and more 7 locations

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: isatuximab SAR650984
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Carfilzomib

First Posted Date: 2020-07-07

Last Posted Date: 2025-03-24

Lead Sponsor: Sanofi

Target Recruit Count: 586

Registration Number: NCT04458831

Locations: 🇩🇪
Investigational Site Number : 2760003, Berlin, Germany
🇩🇪
Investigational Site Number : 2760041, Berlin, Germany
🇫🇷
Investigational Site Number : 2500011, Vannes Cedex, France

and more 126 locations

Home Terms & Conditions Privacy Policy